Zantac NDMA Cancer Lawsuits

Settled Mass-tort payouts ($50k+) mass_tort · pharma

Zantac (ranitidine) NDMA cancer settlements - state court resolutions

Eligibility hint

Took Zantac or generic ranitidine regularly and were diagnosed with stomach, bladder, esophageal, liver, or pancreatic cancer

Estimated payout range

$10,000 – $500,000

Current score

0.62 / 1.00

Official source

View source →

Ranitidine (brand Zantac) was removed from market in 2020 after FDA found it could form the carcinogen NDMA during storage. The federal MDL was largely dismissed in December 2022. State-court cases continued; GSK, Sanofi, Pfizer and Boehringer Ingelheim have reached confidential settlements covering tens of thousands of state cases. Stomach, bladder, esophageal, liver and pancreatic cancer diagnoses with documented Zantac use are the typical eligibility profile.

Recent signals

CL filing: Deutsche Finance America LLC v. Bayerische Versorgungskammer courtlistener_search · 2026-10-17
CL filing: XERIS PHARMACEUTICALS, INC. v. RISING PHARMA HOLDINGS, INC. courtlistener_search · 2026-10-16
CL filing: XERIS PHARMACEUTICALS, INC. v. TORRENT PHARMA INC. courtlistener_search · 2026-10-16
CL filing: CUNNINGHAM-BEAMON v. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. courtlistener_search · 2026-09-30
CL filing: HOPKINS v. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. courtlistener_search · 2026-09-30
CL filing: BROWN v. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. courtlistener_search · 2026-09-30
CL filing: SMITH v. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. courtlistener_search · 2026-09-29
Exhibit 53 - Newman From Powders to Single Crystals regulations_gov · 2026-09-16
Exhibit 38 - Draft Guidance - Sameness Evaluation in ANDA regulations_gov · 2026-09-16
Exhibit 57 - Guidance - ANDAs Pharmaceutical Solid Polymorphism regulations_gov · 2026-09-16

Brands: sanofigskglaxosmithklinepfizerboehringer ingelheim
Products: zantacranitidinendma

Frequently asked questions

Who qualifies for the Zantac NDMA Cancer Lawsuits settlement?

You may qualify if the following applies to you: Took Zantac or generic ranitidine regularly and were diagnosed with stomach, bladder, esophageal, liver, or pancreatic cancer. Eligibility criteria can change as the settlement develops.

How much could a Zantac NDMA Cancer Lawsuits claim be worth?

Estimated payouts range from $10,000 to $500,000 depending on individual circumstances. These are estimates based on comparable outcomes, not guarantees.

What is the current status of the Zantac NDMA Cancer Lawsuits settlement?

Settled. Ranitidine (brand Zantac) was removed from market in 2020 after FDA found it could form the carcinogen NDMA during storage. The federal MDL was largely dismissed in December 2022. State-court cases continued; GSK, Sanofi, Pfizer and Boehringer Ingelheim have reached confidential settlements covering tens of thousands of state cases. Stomach, bladder, esophageal, liver and pancreatic cancer diagnoses with documented Zantac use are the typical eligibility profile.

How do I check whether I'm included?

Take the free 30-second audit at https://getclaimscout.com/audit and claimscout matches the brands and products you've used against every active class action settlements and mass torts it tracks, or review the eligibility details at https://getclaimscout.com/matters/zantac-ndma.

Think this might apply to you?
Take a 30-second audit and we'll match every brand you've used against active settlements.

Start audit →

On iPhone? Get the Claimscout app and follow this settlement for updates.

Building an AI agent? This matter is available as JSON at https://getclaimscout.com/api/v1/matters/zantac-ndma, and the full registry is at /api/v1/matters. Agent quickstart: /llms.txt. Schema: /openapi.json.